Floatz logo

Anti-Tumor Necrosis Factor Receptor Superfamily Member 8 Chimeric Antigen Receptor T Cells

Lymphoma, T-Cell, Peripheral

National Cancer Institute (NCI)Cell therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

136 Active assets in the Lymphoma, T-Cell, Peripheral cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Tarapeutics Science Inc.
Phase 4BBB
Inno-206
BeBetter Med Inc
Phase 4BBB
Pralatrexate
Peking University People's Hospital
Phase 4BBB
(+)-VINCRISTINE
BeBetter Med Inc
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB

View all 50 →

Same molecule, other indications

Anti-Tumor Necrosis Factor Receptor Superfamily Member 8 Chimeric Antigen Receptor T Cells is also rated in:

anaplastic large cell lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
Lymphoma, Extranodal NK-T-CellDormant
CC
Indicative ·
47 / 100
View asset →
enteropathy-associated T-cell lymphomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →